Regeneron awarded over $400 million in damages in US antitrust suit against Amgen
Amgen must pay $271.2 million in punitive damages and $135.6 million in compensatory damages to Regeneron Pharmaceuticals, a Delaware federal jury said, finding that Amgen broke antitrust and tort laws by...To view the full article, register now.
Already a subscriber? Click here to view full article